Shaping Corporate Strategy and Narrative in Non-Opioid Pain
Sector
Biotech
Company
Emerging Biotech
Therapeutic Area
Pain / Neuroscience
Treatment Modality
Small Molecule
Product Stage
Clinical
Expertise
Corporate
An emerging biotechnology company advancing a portfolio of non-opioid pain therapies sought to strengthen its corporate positioning as it prepared for upcoming clinical and financing milestones. Operating in a field under intense scrutiny due to the opioid crisis, the company needed a cohesive strategy to differentiate its science, highlight the unmet need, and ensure its story resonated with investors, partners, and broader stakeholders.
Situation
An emerging biotechnology company advancing a portfolio of non-opioid pain therapies sought to strengthen its corporate positioning as it prepared for upcoming clinical and financing milestones. Operating in a field under intense scrutiny due to the opioid crisis, the company needed a cohesive strategy to differentiate its science, highlight the unmet need, and ensure its story resonated with investors, partners, and broader stakeholders.
Situation
Approach
We partnered with leadership to refine corporate strategy and corporate affairs, aligning internal priorities with external expectations. This included clarifying the company’s positioning within the pain management landscape, sharpening the value story for its non-opioid approach, and developing a corporate narrative that bridged rigorous scientific data with policy, advocacy, and investor perspectives. We also supported external communications to ensure the message carried consistently across scientific, medical, and corporate audiences.
Approach
Results
The result was a more unified and strategically grounded corporate platform. By aligning strategy with story, the company entered its next stage of growth with greater clarity, credibility, and resonance across stakeholders in the pain management ecosystem.
Situation
An emerging biotechnology company advancing a portfolio of non-opioid pain therapies sought to strengthen its corporate positioning as it prepared for upcoming clinical and financing milestones. Operating in a field under intense scrutiny due to the opioid crisis, the company needed a cohesive strategy to differentiate its science, highlight the unmet need, and ensure its story resonated with investors, partners, and broader stakeholders.
Approach
We partnered with leadership to refine corporate strategy and corporate affairs, aligning internal priorities with external expectations. This included clarifying the company’s positioning within the pain management landscape, sharpening the value story for its non-opioid approach, and developing a corporate narrative that bridged rigorous scientific data with policy, advocacy, and investor perspectives. We also supported external communications to ensure the message carried consistently across scientific, medical, and corporate audiences.
Results
The result was a more unified and strategically grounded corporate platform. By aligning strategy with story, the company entered its next stage of growth with greater clarity, credibility, and resonance across stakeholders in the pain management ecosystem.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—sharper, faster, and leaner.
Connect with our Biography team to start a conversation.